ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.465,69
-0,03%
S&P 500
5.180,74
1,03%
US Dollar vs BRL
5,0764
0,00%
Bitcoin
63.848,09
1,08%
Brent Oil
82,995
-0,58%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Immunovant Inc (IMVT)

  7. Immunovant Inc (IMVT) Notícias

IMVT

Immunovant (IMVT)

Immunovant Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMVT
DataHoraFonteTítuloCódigoCompanhia
12/03/202408:30GlobeNewswire Inc.Immunovant Awarded U.S. Patent for IMVT-1402NASDAQ:IMVTImmunovant Inc
23/02/202418:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
14/02/202410:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMVTImmunovant Inc
12/02/202409:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMVTImmunovant Inc
12/02/202409:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMVTImmunovant Inc
16/01/202409:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
03/01/202410:00GlobeNewswire Inc.Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IMVTImmunovant Inc
20/12/202319:40Dow Jones NewsImmunovant Gets Positive Data From Graves' Disease Treatment TrialNASDAQ:IMVTImmunovant Inc
20/12/202318:30GlobeNewswire Inc.Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:IMVTImmunovant Inc
20/12/202318:30GlobeNewswire Inc.Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:IMVTImmunovant Inc
28/11/202309:00GlobeNewswire Inc.Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:IMVTImmunovant Inc
28/11/202309:00GlobeNewswire Inc.Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:IMVTImmunovant Inc
13/11/202310:00GlobeNewswire Inc.Immunovant to Present at Upcoming Investor ConferencesNASDAQ:IMVTImmunovant Inc
09/11/202310:49Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:IMVTImmunovant Inc
09/11/202309:00GlobeNewswire Inc.Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023NASDAQ:IMVTImmunovant Inc
02/10/202317:52GlobeNewswire Inc.Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:IMVTImmunovant Inc
29/09/202317:48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMVTImmunovant Inc
28/09/202307:09Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:IMVTImmunovant Inc
28/09/202300:41GlobeNewswire Inc.Immunovant Announces Pricing of $450 Million Common Stock FinancingNASDAQ:IMVTImmunovant Inc
26/09/202318:18KR Market News장기간 고금리와 美 정부 폐쇄 우려로 월스트리트 하락NASDAQ:IMVTImmunovant Inc
26/09/202318:00GlobeNewswire Inc.Immunovant Announces Proposed Offering of $300 Million of Common StockNASDAQ:IMVTImmunovant Inc
26/09/202307:00GlobeNewswire Inc.Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsNASDAQ:IMVTImmunovant Inc
26/09/202300:01GlobeNewswire Inc.Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023NASDAQ:IMVTImmunovant Inc
10/08/202308:00GlobeNewswire Inc.Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023NASDAQ:IMVTImmunovant Inc
26/06/202308:36Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:IMVTImmunovant Inc
26/06/202308:27Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:IMVTImmunovant Inc
22/05/202312:50Dow Jones NewsImmunovant Shares Touch 52-Week High After FDA Green Lights IMVT-1402 StudyNASDAQ:IMVTImmunovant Inc
22/05/202308:12Edgar (US Regulatory)Annual Report (10-k)NASDAQ:IMVTImmunovant Inc
22/05/202308:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IMVTImmunovant Inc
22/05/202308:00GlobeNewswire Inc.Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023NASDAQ:IMVTImmunovant Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMVT

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
MNPR3
MINUPAR ON
BOV
ENAT3
ENAUTA ON
BOV
PRIO3
PETRORIO ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
TELB4
TELEBRAS PN
BOV
COGN3
COGNA ON
BOV
GOLL4
GOL PN
BOV
BHIA3
Grupo Casas Bahia ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados